Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.55 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.52 |
| ▸ | FDPS | P14324 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Demelverine SCHEMBL1516521 | 0.81 | SIGMAR1 (0.76) | TAAR1SIGMAR1AOC3FDPS | |
| SCHEMBL1176965 | 0.81 | MAOA (0.67) | TAAR1SIGMAR1AOC3ALDH1A1 | |
| SCHEMBL10690113 | 0.81 | TAAR1 (0.55) | TAAR1SIGMAR1AOC3 | |
| SCHEMBL2584302 | 0.80 | PYCR1 (0.66) | SIGMAR1AOC3ALDH1A1 | |
| Hydrochloric Acid SCHEMBL28077090 | 0.79 | LMNA (0.68) | TAAR1SIGMAR1AOC3ALDH1A1 | |
| SCHEMBL9768687 | 0.79 | SIGMAR1 (0.73) | TAAR1SIGMAR1AOC3FDPS | |
| Oxalic Acid SCHEMBL10689565 | 0.78 | TAAR1 (0.49) | TAAR1SIGMAR1AOC3FDPS | |
| SCHEMBL1300012 | 0.76 | TAAR1 (0.59) | TAAR1SIGMAR1AOC3FDPS | |
| Demelverine SCHEMBL7778459 | 0.76 | SIGMAR1 (0.63) | TAAR1SIGMAR1AOC3FDPSALDH1A1 | |
| SCHEMBL8293202 | 0.75 | TAAR1 (0.64) | TAAR1SIGMAR1AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070015759-A1 | Metasubstituted thiazolidinones, their manufacture and use as a drug | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015759-A1 | Metasubstituted thiazolidinones, their manufacture and use as a drug | PLK4, PDXK, PLK2 | TAAR1 4374/4885SIGMAR1 3314/4885AOC3 4053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.